OncoSec Medical (NSDQ:ONCS) today priced an underwritten public offering of 13,333,334 shares of its common stock at $1.50 apiece.
The San Diego, Calif.-based company expects the offering to bring in $20 million to help fund its Phase II melanoma trial, as well as other clinical and R&D activities.
Get the full story at our sister site, Drug Delivery Business News.